Long-await­ed No­vavax PhI­II re­sults show 90.3% over­all ef­fi­ca­cy, with 100% ef­fec­tive­ness against mod­er­ate and se­vere Covid-19

Af­ter sev­er­al months of de­lays and set­backs, the small Mary­land biotech No­vavax has fi­nal­ly com­plet­ed its North Amer­i­can Phase III tri­al for its Covid-19 vac­cine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER